AlphaNet's Impact on individuals with Alpha-1
AlphaNet facilitates vital support and innovative solutions for individuals with Alpha-1 Antitrypsin Deficiency.
Funding Breakthrough
Over the past 25 years, AlphaNet has donated more than $70 million to the Alpha-1 Foundation to help fund research, community programs, and patient education through long-standing partnerships with all pharmaceutical companies in the Alpha-1 space.
Expert Coordinators
AlphaNet has established an extensive peer-to-peer network consisting of over 70 Coordinators who serve 7,500 patients throughout the United States and Canada.
Drug Compliance Excellence
Adherence rates for weekly infusions for all pharma companies are 90%+.
Prestigious Publications
Over 50 peer-reviewed papers have been published based on AlphaNet program data and resulted in the completion of more than 20 outcomes studies.
AlphaNet is a not-for-profit organization dedicated to providing innovative disease management services to individuals with the genetic condition Alpha-1 Antitrypsin Deficiency (Alpha-1). AlphaNet empowers individuals with Alpha-1 (Alphas) to take charge of their health and is committed to funding research for a cure.
Our unique DMN peer-to-peer model stands as a testament to this dedication. Through this approach, we’ve ushered in an era of top-tier disease management services for Alphas. The success stories range from facilitating groundbreaking research to bolstering community support via education and peer guidance.
What underscores the effectiveness of our program is the tangible results. Adherence rates for weekly infusions across all our partner pharmaceutical companies consistently exceed 90%. This speaks not only to the effectiveness of our model but also to the trust Alphas place in us. In line with our mission, our disease management program has been a catalyst in promoting better health habits and, more importantly, enhancing the overall quality of life. Notable improvements observed include reduced emergency visits, fewer unscheduled doctor appointments, and significant positive changes in lifestyle metrics for Alpha-1 patients.
As we stride forward, our focus remains unwavering: to usher in an era of hope, healing, and health for every individual with Alpha-1.
Using the DMN peer-to-peer business model, AlphaNet was able to raise $70 million to date to help fund research, community programs, and patient education, as well as bring adherence rates for weekly infusions for all pharma companies to 90%+.